A dynamic oligopoly structural model for the prescription drug market after patent expiration

International Economic Review

Volumn 51, Issue 4, 2010, Pages 1175-1207

  Ching, Andrew T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649407471     PISSN: 00206598     EISSN: 14682354     Source Type: Journal    
DOI: 10.1111/j.1468-2354.2010.00615.x     Document Type: Article

References (53)

1. Ackerberg, D., "Advertising, Learning and Consumer Choice in Experience Good Markets: A Structural Empirical Examination, " International Economic Review 44 (2003), 1007-40.
2. Ackerberg, D., and M. Rysman, "Unobserved Product Differentiation in Discrete Choice Models: Estimating Price Elasticities and Welfare Effects, " Rand Journal of Economics 36 (2005), 771-88.
3. Aghion, P., P. Bolton, C. Harris, and B. Jullien, "Optimal Learning by Experimentation, " Review of Economic Studies 58 (1991), 621-54.
4. Aghion, P., and M. P. Espinosa, and B. Jullien, "Dynamic Duopoly with Learning through Market Experimentation, " Economic Theory 3 (1993), 517-39.
5. Anderson, S., A. De Palma, and J.-F. Thisse, Discrete Choice Theory of Product Differentiation ( Cambridge, MA MIT Press, 1992).
6. Benkard, C. L., "A Dynamic Analysis of the Market for Wide-bodied Commerical Aircraft, " Review of Economic Studies 71 (2004), 581-611.
7. Bergemann, D., and J. Välimäki, "Market Diffusion with Two-Sided Learning, " Rand Journal of Economics 28 (1997), 773-95.
8. Bergemann, D., and J. Välimäki, "Entry and Vertical Differentiation, " Journal of Economic Theory 106 (2002), 91-125.
9. Berry, S., and A. Pakes, "The Pure Characteristics Discrete Choice Model, " International Economic Review 48 (2007), 1193-225.
10. Berry, S. T., J. Levinshohn, and A. Pakes, "Automobile Prices in Market Equilibrium, " Econometrica 63 (1995), 841-90.
11. Carroll, N. V., C. Siridhara, and J. E. Fincham, "Perceived Risks and Pharmacists' Generic Substitution Behavior, " Journal of Consumer Affairs 20 (1986), 36-47.
12. Carroll, N. V., and A. P. Wolfgang, "Risks, Benefits, and Generic Substitution, " Journal of Consumer Affairs 25 (1991), 110-121.
13. Caves, R. E., M. D. Whinston, and M. A. Hurwitz, "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry, " Brookings Papers on Economic Activity, Microeconomics 1 (1991), 1-48.
14. Cheong, K.-S., and K. Judd, "Mergers and Dynamic Oligopoly, " mimeo, Stanford University, Hoover Institution, 2000.
15. Ching, A.T., Dynamic Equilibrium in U.S. Prescription Drug Market after Patent Expiration, Ph.D. thesis, University of Minnesota, August 2000.
16. Ching, A.T., "Some Observations in the U.S. Prescription Drug Market after Patent Expiration, " Working Paper, Rotman School of Management, University of Toronto, 2004.
17. Ching, A.T., "Consumer Learning and Heterogeneity: The Dynamics of Demand for the Prescription Drug Market after Patent Expiration, " International Journal of Industrial Organization (2010), forthcoming.
18. Ching, A.T., and M. Ishihara, "Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions, ", Working Paper, Rotman School of Management, University of Toronto, 2010a.
19. Ching, A.T., and M. Ishihara, "The Effects of Detailing on Prescribing Decisions Under Quality Uncertainty, " Quantitative Marketing and Economics 8 (2010b), 123-65.
20. Cook, A., "How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, " CBO Study, Congressional Budget Office, July 1998.
21. Crawford, G. S., and M. Shum, "Uncertainty and Experimentation in Pharmacetical Demand, " Econometrica 73 (2005), 1135-74.
22. DeGroot, M. H., Optimal Statistical Decisions ( New York McGraw-Hill, 1970).
23. Dube, J., K. Sudhir, A. Ching, G. Crawford, M. Draganska, J. Fox, W. Hartmann, G. Hitsch, M. Villas-Boas, and N. Vilcassim, "Recent Advances in Structural Econometric Modeling: Dynamic, Product Positioning, and Entry, " Marketing Letters 16 (2005), 209-24.
24. Ellison, G., and S. F. Ellison, "Strategic Entry Deterrence and the Behavior of Pharmaceutial Incumbents Prior to Patent Expiration, " mimeo, Department of Economics, MIT, 2007.
25. Erdem, T., and M. P. Keane, "Decision-making under Uncertainty: Capturing Dynamic Brand Choice Processes in Turbulent Consumer Goods Markets, " Marketing Science 15 (1996), 1-20.
26. Ericson, R., and A. Pakes, "Markov-Perfect Industry Dynamics: A Framework for Empirical Work, " Review of Economic Studies 62 (1995), 53-83.
27. Fershtman, C., and A. Pakes, "A Dynamic Oligopoly with Collusion and Price Wars, " Rand Journal of Economics 31 (2000), 207-36.
28. Frank, R. G., and D. S. Salkever, "Pricing Patent Loss and the Market for Pharmaceuticals, " Southern Economic Journal 59 (1992), 165-79.
29. Frank, R. G., and D. S. Salkever, "Generic Entry and the Pricing of Pharmaceuticals, " Journal of Economics and Management Strategy 6 (1997), 75-90.
30. Gallant, R., H. Hong, and A. Khwaja, "Dynamic Entry with Cross Product Spillovers: An Application to the Generic Drug Industry, " Working Paper, Fuqua School of Business, Duke University, 2009.
31. Gowrisankaran, G., "A Dynamic Model of Endogenous Horizontal Mergers, " Rand Journal of Economics 30 (1999), 56-83.
32. Gowrisankaran, G., and R. Town, "Dynamic Equilibrium in the Hospital Industry, " Journal of Economics and Management Strategy 24 (1997), 885-94.
33. Grabowski, H., and J. Vernon, "Longer Patents for Lower Imitation Barriers: The 1984 Drug Act, " American Economic Review and Proceedings 76 (1986), 195-98.
34. Grabowski, H., and J. Vernon, "Pioneer, Imitators, and Generics-A Simulation Model of Schumpeterian Competition, " Quarterly Journal of Economics 101 (1987), 491-525.
35. Grabowski, H., and J. Vernon, "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act, " Journal of Law and Economics 35 (1992), 331-50.
36. Griliches, Z., and I. Cockburn, "Generics and New Goods in Pharmaceutical Price Indexes, " American Economic Review (December 1994), 1213-32.
37. Harrington, J., "Experimentation and Learning in a Differentiated-Products Duopoly, " Journal of Economic Theory 66 (1995), 275-88.
38. Heckman, J., and B. Singer, "A Method of Minimizing the Impact of Distributional Assumptions in Econometric Models for Duration Data, " Econometrica 52 (1984), 271-320.
39. Keller, G., and S. Rady, "Market Experimentation in a Dynamic Differentiated-Goods Duopoly, " mimeo, Stanford University and LSE, 1998.
40. Maskin, E., and J. Tirole, "A Theory of Dynamic Oligopoly: I & II, " Econometrica 56 (1988), 549-600.
41. Mason, J. B., and W. O. Bearden, "Generic Drugs: Consumer, Pharmacist and Physician Perception of the Issues, " Journal of Consumer Affairs 14 (1980), 192-205.
42. McLennan, A., "Price Dispersion and Incomplete Learning in the Long-Run, " Journal of Economic Dynamics and Control 7 (1984), 331-47.
43. Meadows, M., "Greater Access to Generic Drugs: New FDA Initiatives to Improve Drug Reviews and Reduce Legal Loopholes, " FDA Consumer Magazine, September-October issue (2003).
44. Pakes, A., and P. McGuire, "Computing Markov Perfect Nash Equilibria: Numerical Implications of a Dynamic Differentiated Product Model, " Rand Journal of Economics 25 (1994), 555-89.
45. Pakes, A., and P. McGuire, "Stochastic Approximation for Dynamic Models: Markov Perfect Equilibrium and the 'Curse of Dimensionality', " Econometrica 69 (2001), 1261-82.
46. Reiffen, D., and M. Ward, "Generic Drug Industry Dynamics, " The Review of Economics and Statistics 87 (2005), 37-49.
47. Rothschild, M., "A Two-Armed Bandit Theory of Market Pricing, " Journal of Economic Theory 9 (1974), 185-202.
48. Scott Morton, F. M., "Entry Decisions in the Generic Pharmaceutical Industry, " Rand Journal of Economics 30 (1999), 421-40.
49. Scott Morton, F. M., "Barriers to Entry, Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry, " International Journal of Industrial Organization 18 (2000), 1085-104.
50. Strutton, H. D., J. R. Lumpkin, and S. J. Vitell, "The Elderly's Perceptions of the Risk of Generic Over-the-Counter Medication, " Journal of Research in Pharmaceutical Economics 4 (1992), 25-39.
51. Suh, D.-C., S. W. Schondelmeyer, W. G. Manning, R. S. Hadsall, and J. A. Nyman, "Price Trends before and after Patent Expiration in the Pharmaceutical Industry, " Journal of Research in Pharmaceutical Economics 9 (1998), 17-31.
52. U.S. Congress, Office of Technology Assessment "Pharmaceutical R&D: Cost, Risks and Rewards, " Washington, 1993.
53. Wiggins, S. N., and R. Maness, "Price Competition in Pharmaceuticals: The Case of Antiinfectives, " Economic Inquiry 42 (2004), 247-63.